The Pharma Data

NOVEMBER 5, 2020

billion versus third quarter 2019 (4). billion versus third quarter 2019. billion versus third quarter 2019. REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Total revenues increased by 32% to $2.294 billion in the third quarter of 2020, compared to $1.744 billion in the third quarter of 2019.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

NOVEMBER 20, 2020

“The casirivimab and imdevimab antibody cocktail is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D. Yancopoulos, M.D., President and Chief Scientific Officer of Regeneron.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

.” “REGEN-COV2 is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterly period ended September 30, 2020.

FDA 40

FDA Clinical Trials Hospitals Production 40

The Pharma Data

DECEMBER 29, 2020

About Regeneron Antibody Cocktail Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Agency IQ

OCTOBER 27, 2023

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

JANUARY 5, 2021

Telemedicine isn’t new, but the COVID-19 pandemic has really put the technology front and center, with clinics closing for certain services after state and local governments issued stay-at-home orders to help prevent the spread of the virus. Researchers compared data from February to June in 2019 and February to June 2020.

Doctors 52

Doctors Pharmacy Vaccine Licensing 52

The Pharma Data

JANUARY 17, 2021

The medicine, an anti-SARS-CoV-2 immunoglobulin, given subcutaneously, would provide immediate protection after exposure to the virus and could be used to protect the elderly and healthcare workers. In 2019, Grifols’ economic impact in its core countries of operation was 8.5 BARCELONA, Spain , Jan. billion euros.

Clinical Trials 52

Clinical Trials Treatment Trials Virus 52

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 25, 2024

3 Evidence on transmission of hepatitis C virus (HCV) is less clear, but in Europe, where SSPs are more widely used, high SSP use is associated with a 76% reduction in HCV transmission. Impact of an unsanctioned safe consumption site on criminal activity, 2010-2019. 6 SSPs also may distribute fentanyl test strips. Drug Alcohol Depend.

Drugs 119

Drugs Treatment Disease Science 119

Agency IQ

SEPTEMBER 29, 2023

Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

OCTOBER 14, 2020

In 2019, as reported in the New England Journal of Medicine, the PALM Trial was stopped early following a pre-specified interim analysis that showed superiority of Inmazeb to ZMapp and remdesivir with respect to mortality. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. 2019; 381(24):2293-2303.

FDA Approval 52

FDA Approval FDA Production Treatment 52